ESR1 and breast cancer: In HR+ breast cancer oestrogen receptor mutations (ESR1)23, MAP kinase (MAPK) pathway mutations11,24, and transcription factor alterations11 such as ARID1A mutations11,25,26, are acquired as mechanism of resistance to prior endocrine therapy.